证券代码：688319 证券简称：欧林生物 公告编号：2025-040 成都欧林生物科技股份有限公司 2025 年 半年度募集资金存放、管理与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意成都欧林生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】1397 号）文件核准，公司向社 会公开发行人民币普通股 40,530,000.00 股，实际发行人民币普通股 40,530,000.00 股，发行价为每股人民币 9.88 元。本次募集资金总额为人民币 400,436,400.00 元，扣减含税承销费、保荐费等发行费用人民币 41,599,126.62 元（含税），募 集资金净额为人民币 358,837,273.38 元，上述募集资金已于 2021 年 6 月 2 日到 账。中勤万信会计师事务所（特殊普通合伙）对本次募集资金到位情况进行了审 验，并于 2021 年 6 月 3 日出具了勤信验字【 ...

New Stock Offerings - Shenke Co., Ltd. (002633) has an offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has an offer period from August 12, 2025, to September 10, 2025[1] - ST Gaohong (000851) has an announcement on August 26, 2025[1] Market Volatility - Great Wall Military Industry (601606) reported severe abnormal fluctuations on August 14, 2025[1] - Dongxin Co., Ltd. (688110) had an announcement on August 16, 2025, regarding market conditions[1] - Changfei Optical Fiber (601869) has an announcement dated August 27, 2025, related to market performance[1] Company Announcements - ST Dehao (002005) has an announcement on August 27, 2025, regarding its market status[1] - China Satellite (600118) announced updates on August 27, 2025[1] - ST Yizhong (603389) has an announcement dated August 26, 2025, regarding its market activities[1]

New Stock Issuance - The new stock issuance for Sanxie Electric (证券代码: 920100) is priced at 8.83[1] - Shenkou Co. (证券代码: 002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (证券代码: 600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] Market Alerts - Changcheng Military Industry (证券代码: 601606) is experiencing severe abnormal fluctuations[1] - ST Yanzhen (证券代码: 603389) has reported significant trading anomalies[1] - ST Zhongdi (证券代码: 000609) has been flagged for unusual trading activity[1] Other Notable Stocks - Zhanjiang Development (证券代码: 000753) and Pudong Construction (证券代码: 600284) are also under scrutiny for trading irregularities[1] - The stock of Zhaoyi Innovation (证券代码: 603986) is being monitored for potential volatility[1] - The stock of ST Suwu (证券代码: 600200) has been highlighted for its trading behavior[1]

证券之星消息，8月26日生物制品板块较上一交易日下跌1.13%，欧林生物领跌。当日上证指数报收于 3868.38，下跌0.39%。深证成指报收于12473.17，上涨0.26%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688163 | 赛伦生物 | 26.63 | 4.15% | 5.69万 | | 1.57亿 | | 688331 | 荣昌生物 | 85.27 | 3.76% | 14.72万 | | 12.90亿 | | 002007 | 华兰生物 | 17.72 | 2.07% | 41.07万 | | 7.27亿 | | 002252 | 十八典出 | 7.18 | 1.84% | 102.52万 | | 7.38亿 | | 300239 | 东宝生物 | 6.08 | 1.84% | 16.49万 | | 9966.61万 | | 600867 | 通化东宝 | 8.71 | 1.16% | 60.19万 | | 5.29亿 | | ...

Group 1 - The innovative drug sector in the A-share market has experienced a decline, with several companies showing significant drops in stock prices [1] - Yuan Dong Biological fell over 8%, while Sunshine Nuohe dropped over 6%, and other companies like Haitai Biological and Guangshantang saw declines exceeding 5% [1] - The overall trend indicates a challenging environment for the innovative drug sector, as multiple companies are facing downward pressure on their stock performance [1] Group 2 - Specific stock performance data shows Yuan Dong Biological at -8.86% with a market capitalization of 11.4 billion, and Sunshine Nuohe at -6.99% with a market cap of 8.334 billion [2] - Other notable declines include Haitai Biological at -5.87% (7.32 billion), Guangshantang at -5.49% (22.9 billion), and Yifang Biological at -4.88% (23.2 billion) [2] - Year-to-date performance reveals that despite recent declines, some companies like Guangshantang and Aong Likang have shown substantial increases of 339.58% and 304.97% respectively [2]

Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]

Group 1 - The core point of the article highlights the recent decline in the stock price of Olin Bio, which fell by 5.05% to 31.02 CNY per share, with a trading volume of 174 million CNY and a turnover rate of 1.35%, resulting in a total market capitalization of 12.592 billion CNY [1] - Olin Bio, established on December 11, 2009, and listed on June 8, 2021, specializes in the research, production, and sales of human vaccines. The main revenue composition includes: 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, 3.99% from Haemophilus influenzae type b conjugate vaccine, 0.47% from other (supplementary), and 0.07% from refined tetanus toxin raw liquid [1] Group 2 - From the perspective of major fund holdings, data shows that one fund under Fuyong Fund has a significant position in Olin Bio. The Fuyong Medical Health Mixed Fund A (015655) held 17,200 shares in the first quarter, accounting for 2.06% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 28,400 CNY [2] - The Fuyong Medical Health Mixed Fund A (015655) was established on June 28, 2022, with a latest scale of 11.8186 million CNY. Year-to-date returns are 14.22%, with a one-year return of 10.55%, and a cumulative loss of 20.8% since inception [2]

Core Points - The stock price of Olin Bio (688319) closed at 32.67 yuan, down 1.51% as of August 25, 2025 [1] - The company reported a total revenue of 87.49 million yuan for Q1 2025, representing a year-on-year growth of 23.58% [1] - Net profit attributable to shareholders was 7.07 million yuan, up 72.79% year-on-year [1] - The company has a current ratio of 1.606 and a quick ratio of 1.448, with a debt-to-asset ratio of 47.67% [1] Financial Performance - Total revenue for Q1 2025: 87.49 million yuan, up 23.58% year-on-year [1] - Net profit: 7.07 million yuan, up 72.79% year-on-year [1] - Non-recurring net profit: 11.02 million yuan, up 60.40% year-on-year [1] - Current ratio: 1.606 [1] - Quick ratio: 1.448 [1] - Debt-to-asset ratio: 47.67% [1] Company Overview - Chengdu Olin Bio Technology Co., Ltd. was established in 2009 and is located in Chengdu [2] - The company primarily operates in the pharmaceutical manufacturing industry [2] - Registered capital: 405.93 million yuan, paid-in capital: 50 million yuan [1] - Legal representative: Fan Shaowen [1] Investment and Intellectual Property - The company has invested in 5 enterprises and participated in 741 bidding projects [2] - It holds 31 trademark registrations and 279 patent applications [2] - The company has obtained 116 administrative licenses [2]

New Stock Issuance - New stock issuance for Huaxin Jingke at a price of 18.60 on August 25, 2025[1] - Shenkou Co. (stock code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Market Alerts - Dongxin Co. (stock code: 688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (stock code: 600200) and ST Zhongdi (stock code: 000609) both have announcements dated August 25, 2025[1] - Multiple companies including Zhehai Deman (stock code: 688577) and Huaguang Huaneng (stock code: 600475) have announcements related to abnormal fluctuations on August 23, 2025[1] Additional Information - The report includes links to detailed announcements for various companies, providing transparency and access to further information[1] - The document highlights the importance of monitoring stock performance and market trends for informed investment decisions[1]

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]